Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

92.84 +2.51 (+2.78%)
Streaming Delayed Price Updated: 11:45 AM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
26 27 Next >
News headline image
NASDAQ:INCY stands out as a growth opportunity that won't break the bank. ↗
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering. 
Via Chartmill
News headline image
Exit Now! 3 Biotech Stocks to Sell in February 2024 ↗
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability. 
Via InvestorPlace
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
The Analyst Verdict: Incyte In The Eyes Of 8 Experts ↗
 
Via Benzinga
News headline image
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
From Incyte
Via Business Wire
News headline image
NASDAQ:INCY is not too expensive for the growth it is showing. ↗
INCYTE CORP (NASDAQ:INCY) is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
Expert Ratings for Incyte ↗
 
Via Benzinga
News headline image
What's Up With Incyte Stock Lately? ↗
Incyte Corporation (NASDAQ: INCY) shares are trading higher on Tuesday. The stock has risen rapidly since Monday. 
Via Benzinga
News headline image
Earnings Scheduled For February 13, 2024 ↗
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
News headline image
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued. ↗
INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Pancreatic Cancer Treatments Poised for Major Advances in 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B ↗
Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat. 
Via Benzinga
News headline image
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion ↗
Novartis will add to its cancer treatment pipeline with via the German biotech. 
Via Investor's Business Daily
News headline image
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
From Incyte
Via Business Wire
News headline image
Why Is MorphoSys (MOR) Stock Up 50% Today? ↗
News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock. 
Via InvestorPlace
News headline image
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer ↗
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold... 
Via Benzinga
News headline image
5 top healthcare stocks for earnings growth in 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
News headline image
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
From Incyte
Via Business Wire
News headline image
NASDAQ:INCY is probably undervalued for the fundamentals it is displaying. ↗
For those who appreciate value investing, INCYTE CORP (NASDAQ:INCY) is a compelling option with its solid fundamentals. 
Via Chartmill
News headline image
3 Pharma Stocks Could Be the Pills Your Portfolio Needs ↗
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations. 
Via InvestorPlace
News headline image
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations ↗
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to  
Via Benzinga
News headline image
In the world of growth stocks, NASDAQ:INCY shines as a value proposition. ↗
Investors seeking growth at a reasonable cost should explore INCYTE CORP (NASDAQ:INCY). 
Via Chartmill
News headline image
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
From Incyte
Via Business Wire
News headline image
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals. ↗
In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
NASDAQ:INCY is showing decent growth, but is still valued reasonably. ↗
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering. 
Via Chartmill
News headline image
AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
The 3 Most Undervalued Biotech Stocks to Buy in December ↗
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. 
Via InvestorPlace
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
From Incyte and Syndax Pharmaceuticals
Via Business Wire
News headline image
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets ↗
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%). 
Via Benzinga
Topics Stocks
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.